Barclays analyst Gena Wang maintains $Sarepta Therapeutics (SRPT.US)$ with a buy rating, and maintains the target price at $209.
According to TipRanks data, the analyst has a success rate of 42.1% and a total average return of 8.1% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Sarepta Therapeutics (SRPT.US)$'s main analysts recently are as follows:
The company's Q3 results significantly exceeded expectations with impressive revenues for both total and Elevidys. Despite the company's maintained guidance for Elevidys, it is perceived as somewhat cautious.
Sarepta's sales of Elevidys and exon-skipping franchise exceeded market expectations, and the company's outlook for Q4 Elevidys remains strong, potentially leading to additional positive results, provided there is limited impact from the holiday season. There exists a possibility for an increase in the FY25 guidance come January, although current market valuations reflect a perception of the franchise having a five-year trajectory until the exclusivity is lost.
Sales of Elevidys exhibited growth surpassing expectations in Q3, accompanied by optimistic remarks from management regarding the product's launch. It is believed that all indicators are suggestive of Elevidys' potential to become a product generating several billions in revenue, which could be further enhanced by a series of gene therapy introductions anticipated over the ensuing five years.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
巴克莱银行分析师Gena Wang维持$Sarepta Therapeutics (SRPT.US)$买入评级，维持目标价209美元。
根据TipRanks数据显示，该分析师近一年总胜率为42.1%，总平均回报率为8.1%。
此外，综合报道，$Sarepta Therapeutics (SRPT.US)$近期主要分析师观点如下：
本公司Q3业绩显著超出预期，总体和Elevidys的营业收入表现令人印象深刻。尽管公司对Elevidys的维持指引被视为有些谨慎。
Sarepta的Elevidys和exon-skipping专利的销售超出了市场预期，公司对Q4的Elevidys前景仍然强劲，可能会带来额外的正面结果，前提是假日季节的影响有限。存在着一种可能性，在1月份提高FY25指引，尽管当前市场估值反映了对该专利在失去独家性之前有五年的发展轨迹的看法。
Elevidys在Q3表现出的销售增长超出了预期，并伴随着管理层对产品推出的乐观评述。相信所有的因子都暗示了Elevidys有潜力成为一个创造数十亿营业收入的产品，这一潜力有望在接下来的五年中通过一系列基因疗法的推出得到进一步提升。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
